Neuren Pharmaceuticals Ltd has released a press release.
Q3 2024 update
Filed with ASX ·
On 6ix: 6ix.com/news/q3-2024-update-1
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- PRV sold for US$150m - Neuren to receive one third
- DAYBUE receives marketing authorization in Canada
- NEU continues PMS P3 preparations after positive FDA meeting
- Phase 2 trial shows significant improvements in Angelman
- Q2 2024 update
Later from Neuren Pharmaceuticals
- Neuren announces A$50m on-market share buy-back program
- Trofinetide marketing application submitted in Europe
- Priority Review Voucher sale proceeds received
- Fast Track granted by FDA for NNZ-2591 in Pitt Hopkins
- Neuren receives Rare Pediatric Disease Designation from FDA
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals